格隆汇1月4日丨脑动极光-B(06681.HK)宣布，公司间接全资附属公司浙江脑动极光医疗科技有限公司 ("浙江脑动极光")已与北京健国医疗科技有限公司("北京健国医疗")正式签署《认知数字疗法项目合作协 议》。双方将于2026年1月1日至2026年12月30日期间，围绕「认知功能评估训练精神卫生应用场景构建 与推广应用」课题开展深度合作，共同推动认知障碍数字疗法的标准化、规模化与可及化。 1.国标研究：联合研制认知障碍数字疗法核心技术指标体系、临床验证路径与应用规范，为国家标准立 项提供循证数据与草案文本。 本次合作是公司继参与国家科技重大专项及获批认知障碍数字疗法北京市重点实验室后，在认知障碍数 字疗法应用落地与生态构建方面的又一重要举措。 2.多中心试点：在杭州、南宁、武汉、牡丹江等地精神卫生福利机构及社区同步落地「脑动极光认知功 能评估与训练系统」，预计覆盖80%的目标机构，形成可复制的干预路径。 据悉，北京健国医疗依托北京健国科技集团在高端医疗科技领域的深厚产业基础和项目管理经验，专注 于康复医学技术的临床转化与推广。此次合作，正是双方将前沿数字诊疗算法与成熟产业化体系相结合 的实践，旨在共同推动认 ...

Core Viewpoint - The recent inclusion of multiple Hong Kong stocks into the Stock Connect program has led to significant price volatility and increased trading activity, driven by various factors including index adjustments, new capital inflows, speculative trading, and limited share availability [1][2][4]. Group 1: Stock Performance - Several stocks, such as药捷安康-B and佰泽医疗, experienced dramatic price movements after being included in the Stock Connect, with药捷安康-B seeing a peak increase of over 1000% shortly after inclusion, followed by a sharp decline of 53.73% [2][4]. - The average trading volume for these stocks surged significantly post-inclusion, with some stocks experiencing increases in daily trading volume by several times to dozens of times compared to before [3][4]. Group 2: Reasons for Volatility - The adjustment of index constituents has led to passive buying from ETFs tracking these indices, contributing to the volatility of newly included stocks [4][5]. - The inclusion of these stocks has opened up opportunities for mainland investors, resulting in a notable influx of capital into these stocks [5][6]. - Speculative trading has also played a role, particularly in the healthcare sector, where stocks with innovative drug concepts have attracted attention [6][7]. - Many of the stocks included are relatively new to the market, with limited free-floating shares, making them more susceptible to extreme price fluctuations when capital flows in [6][7].

Group 1 - The company's revenue increased from RMB 51.89 million to RMB 100.05 million for the six months ending June 30, 2025, representing a year-on-year growth of 92.81% [1] - Gross profit rose to RMB 40.85 million, a year-on-year increase of 66.60%, primarily due to a significant increase in system sales and the number of hospitals and patients using the systems [1] - Research and development expenses increased from RMB 64.23 million to RMB 68.15 million, reflecting a year-on-year growth of 6.10% [1] Group 2 - The company has established a broad pipeline of digital therapy products, with core products commercialized for eight indications across four major types of cognitive disorders [2] - The company plans to implement strategies to drive future growth, including expanding system indications, accelerating commercialization, enhancing R&D capabilities, exploring international markets, and seeking strategic acquisition opportunities [2] - The company has helped over 200 hospitals in China establish cognitive centers, including leading hospitals certified as "National Medical Centers" by the National Health Commission [1][2]